TWI833727B - 供每日一次用之苯並咪唑化合物的眼用組成物 - Google Patents

供每日一次用之苯並咪唑化合物的眼用組成物 Download PDF

Info

Publication number
TWI833727B
TWI833727B TW108101861A TW108101861A TWI833727B TW I833727 B TWI833727 B TW I833727B TW 108101861 A TW108101861 A TW 108101861A TW 108101861 A TW108101861 A TW 108101861A TW I833727 B TWI833727 B TW I833727B
Authority
TW
Taiwan
Prior art keywords
cyclodextrin
bilastine
pharmaceutical composition
pharmaceutically acceptable
ophthalmic pharmaceutical
Prior art date
Application number
TW108101861A
Other languages
English (en)
Chinese (zh)
Other versions
TW201932110A (zh
Inventor
岡左龍 赫納多海洛
安娜 岡左龍葛洛汀薩
佩洛 莫藍波拉圖娜
艾圖羅 薩波昂絲
涅韋斯 費納赫拿
坦尼亞 岡左列葛西
帕洛瑪 塔托塞德
弗朗西科 奧特皮納
安索 費納費雷
維多利亞 迪亞多姆
Original Assignee
西班牙商Faes製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西班牙商Faes製藥公司 filed Critical 西班牙商Faes製藥公司
Publication of TW201932110A publication Critical patent/TW201932110A/zh
Application granted granted Critical
Publication of TWI833727B publication Critical patent/TWI833727B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108101861A 2018-01-18 2019-01-17 供每日一次用之苯並咪唑化合物的眼用組成物 TWI833727B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382021 2018-01-18
EP18382021.6 2018-01-18
??18382021.6 2018-01-18

Publications (2)

Publication Number Publication Date
TW201932110A TW201932110A (zh) 2019-08-16
TWI833727B true TWI833727B (zh) 2024-03-01

Family

ID=61017875

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108101861A TWI833727B (zh) 2018-01-18 2019-01-17 供每日一次用之苯並咪唑化合物的眼用組成物

Country Status (28)

Country Link
US (2) US20210128544A1 (cg-RX-API-DMAC7.html)
EP (2) EP3740191B1 (cg-RX-API-DMAC7.html)
JP (1) JP7309729B2 (cg-RX-API-DMAC7.html)
KR (1) KR102695627B1 (cg-RX-API-DMAC7.html)
CN (1) CN111727035B (cg-RX-API-DMAC7.html)
AR (1) AR114216A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019209214B2 (cg-RX-API-DMAC7.html)
CA (1) CA3088740A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001895A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009992A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124270T1 (cg-RX-API-DMAC7.html)
DK (1) DK3740191T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091725A1 (cg-RX-API-DMAC7.html)
ES (1) ES2878107T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211037T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054594T2 (cg-RX-API-DMAC7.html)
LT (1) LT3740191T (cg-RX-API-DMAC7.html)
MA (1) MA51612B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020007692A (cg-RX-API-DMAC7.html)
PL (1) PL3740191T3 (cg-RX-API-DMAC7.html)
PT (1) PT3740191T (cg-RX-API-DMAC7.html)
PY (1) PY1903392A (cg-RX-API-DMAC7.html)
SA (1) SA520412443B1 (cg-RX-API-DMAC7.html)
SI (1) SI3740191T1 (cg-RX-API-DMAC7.html)
TW (1) TWI833727B (cg-RX-API-DMAC7.html)
UY (1) UY38055A (cg-RX-API-DMAC7.html)
WO (1) WO2019141563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202005077B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025508704A (ja) * 2022-02-17 2025-04-10 ファエス・ファルマ・ソシエダッド・アノニマ 1日1回非経口投与のためのビラスチン組成物
CN116211795B (zh) * 2022-12-26 2025-09-26 深圳市贝美药业有限公司 一种比拉斯汀口服液体制剂及其制备方法
CN115970066B (zh) * 2022-12-29 2024-09-27 成都爱睿康乐医疗器械有限公司 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用
WO2024224326A1 (en) * 2023-04-27 2024-10-31 Leiutis Pharmaceuticals Llp Liquid parenteral formulations of bilastine
WO2024224308A1 (en) * 2023-04-27 2024-10-31 Leiutis Pharmaceuticals Llp Liquid parenteral formulations of bilastine free of cyclodextrins
WO2024256956A1 (en) * 2023-06-13 2024-12-19 Leiutis Pharmaceuticals Llp Stable formulations of bilastine for nasal and ophthalmic use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
JP3527256B2 (ja) 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
CA2484460C (en) 2002-04-19 2009-09-29 Faes Farma, S.A. Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-yl]-1-piperidinyl]ethyl]-.alpha..alpha. dimethyl-benzeneacetic acid
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US7247623B2 (en) 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
UA94938C2 (ru) * 2006-03-31 2011-06-25 ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)
SG170044A1 (en) * 2006-03-31 2011-04-29 Vistakon Pharmaceuticals Llc Ocular allergy treatments
JP2010531898A (ja) 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス, インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
期刊 SHYAMALA BHASKARAN Topical ocular drug delivery-Areview Indian Journal of Pharmaceutical Sciences 67(4) 2005 404-408
期刊 Uday B Kompella Recent advances in ophthalmic drug delivery Ther Deliv. 1(3) 2010 September 1 435–456
期刊 Uday B Kompella Recent advances in ophthalmic drug delivery Ther Deliv. 1(3) 2010 September 1 435–456; *
網路文獻 Mark B. Abelson A Recipe for Better Patient Compliance Review of ophthalmology PUBLISHED 2 APRIL 2014
網路文獻 Mark B. Abelson A Recipe for Better Patient Compliance Review of ophthalmology PUBLISHED 2 APRIL 2014;期刊 SHYAMALA BHASKARAN Topical ocular drug delivery-Areview Indian Journal of Pharmaceutical Sciences 67(4) 2005 404-408 *

Also Published As

Publication number Publication date
ZA202005077B (en) 2024-12-18
CA3088740A1 (en) 2019-07-25
EP3740191B1 (en) 2021-04-28
HRP20211037T1 (hr) 2021-10-01
KR102695627B1 (ko) 2024-08-16
AU2019209214A1 (en) 2020-08-13
DK3740191T3 (da) 2021-06-07
PL3740191T3 (pl) 2021-11-29
CN111727035B (zh) 2024-05-28
BR112020014265A2 (pt) 2020-12-08
CY1124270T1 (el) 2022-07-22
MA51612A (fr) 2020-11-25
AU2019209214B2 (en) 2023-11-23
UY38055A (es) 2019-08-30
KR20200111727A (ko) 2020-09-29
PT3740191T (pt) 2021-07-09
MA51612B1 (fr) 2021-06-30
ES2878107T3 (es) 2021-11-18
MX2020007692A (es) 2020-09-14
CO2020009992A2 (es) 2021-01-18
HUE054594T2 (hu) 2021-09-28
WO2019141563A1 (en) 2019-07-25
PY1903392A (es) 2019-08-01
JP7309729B2 (ja) 2023-07-18
LT3740191T (lt) 2021-08-10
JP2021511317A (ja) 2021-05-06
SI3740191T1 (sl) 2021-09-30
AR114216A1 (es) 2020-08-05
SA520412443B1 (ar) 2022-09-01
EP3740191A1 (en) 2020-11-25
EA202091725A1 (ru) 2020-10-12
TW201932110A (zh) 2019-08-16
US20260027099A1 (en) 2026-01-29
CL2020001895A1 (es) 2020-12-04
EP3915539A1 (en) 2021-12-01
CN111727035A (zh) 2020-09-29
US20210128544A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7309729B2 (ja) ビラスチン、β-シクロデキストリンおよび少なくとも1種のゲル化剤を含有する眼科用組成物
AU2017210543B2 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
US11617749B2 (en) Ophthalmic formulations of cetirizine and methods of use
CN106999476A (zh) 用于药物递送和保护眼睛前段的眼用制剂
EA043904B1 (ru) Офтальмологическая композиция, содержащая биластин, бета-циклодекстрин и по крайней мере одно желатинирующее вещество
BR112020014265B1 (pt) Composições oftálmicas de uma vez ao dia de compostos de benzimidazol
US20250228836A1 (en) Bilastine composition for once-daily parenteral administration
HK40034170B (en) Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
HK40034170A (en) Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
WO2025169089A1 (en) Ophthalmic compositions of tyrosine kinase inhibitors and their uses
HK40040553A (en) Ocular formulations for drug-delivery to the posterior segment of the eye
HK1216236B (en) Ocular formulations for drug-delivery to the posterior segment of the eye